Артеріальна гіпертензія у хворих на акромегалію: акцент на кардіоваскулярний ризик

М. Р. Микитюк

doi:10.24026/1818-1384.4(45).2013.78570

Автор(и)

М. Р. Микитюк Інститут проблем ендокринної патології ім. В.Я. Данилевського НАМН України, Харків, Україна

DOI:

https://doi.org/10.24026/1818-1384.4(45).2013.78570

Ключові слова:

acromegaly, arterial hypertension, cardiovascular risk

Анотація

There are several complications of the cardiovascular system caused by acromegaly, especially arterial hypertension (AH). To evaluate AH characteristics in patients with cured-controlled (n=11) acromegaly and with the active disease (n=111). AH was detected in 60,7% of patients. Subjects with active disease showed a positive correlation between IGF-1 and systolic (SBP) and diastolic (DBP) blood pressure (BP) levels (r=0,26, p=0,013) and (r=0,28, p=0,007, respectively), and a positive correlation between insulin like growth factor 1 (IGF-1) and urinary albumin excretion rates (r=0,27, p=0,04). In patients with active disease, IGF-1 was a predictor of SBP. For individuals with cured-controlled disease, waist circumference and age were the predictors associated with SBP and DBP. Our findings suggest that BP levels in patients with active acromegaly are very similar, and depend on excess IGF-1. However, once the disease be comes controlled and IGF-1 levels decrease, their BP levels will depend on the other cardiovascular risk factors.

Біографія автора

М. Р. Микитюк, Інститут проблем ендокринної патології ім. В.Я. Данилевського НАМН України, Харків

M. Mykytyuk

Посилання

Holdaway I.M. Excess mortality in acromegaly [Text] / I.M. Holdaway // Horm. Res. – 2007. – Vol. 68, Suppl. 5. – P. 166-172. https://doi.org/10.1159/000110617

Vitale G. Cardiac abnormalities in acromegaly. Pathophysiology and implications for management [Text] / G. Vitale, R. Pivonello, G. Lombardi [et al.] / Treat. Endocrinol. – 2004. – №3. – P. 309-318. https://doi.org/10.2165/00024677-200403050-00004

AACE Acromegaly Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly [Text] / D. Cook, S. Ezzat, L. Katznelson [et al.] / Endocrinol. Pract. – 2004. – №10. – P. 213-225. https://doi.org/10.4158/ep.10.3.213

Vitale G. Hypertension in acromegaly and in the normal population: prevalence and determinants [Text] / G. Vitale, R. Pivonello, R.S. Auriemma [et al.] / Clin. Endocrinol. (Oxf.). – 2005. – Vol. 63, №4. – P. 470-476. https://doi.org/10.1111/j.1365-2265.2005.02370.x

Bondanelli M. Pathogenesis and prevalence of hypertension in acromegaly [Text] / M. Bondanelli, M.R. Ambrosio, E.C. Uberti / Pituitary. – 2001. – Vol. 4, №4. – P. 239-249. https://doi.org/10.1023/a:1020798430884

Colao A. Cardiovascular consequences of earlyonset growth hormone excess [Text] / A. Colao, L. Spinelli, A. Cuocolo [et al.] // J. Clin. Endocrinol. Metabol. – 2002. – №87. – P. 3097-3104. https://doi.org/10.1210/jc.87.7.3097

Dupuy O. Hypertension and acromegaly in the elderly: French Registry Data [Text] / O. Dupuy, T. Petrossian, L. Bordier [et al.] // Arch. Mal. Coeur. Vaiss. – 2007. – Vol. 100, №8. – P. 660-663.

Criteria for Cure of Acromegaly: A Consensus Statement [Text] / A. Giustina, A. Barkan, F.F. Casanueva, F. Cavagnini // J. Clin. Endocrinol. Metabol. – 2000. – Vol. 85, №2. – P. 526-529. https://doi.org/10.1210/jcem.85.2.6363

World Health Organization. Obesity: Preventing and managing the global epidemic. Technical report series no. 894 [Text]. – Geneva: WHO, 2000. – 23 p.

Alberti K.G. The metabolic syndrome – a new worldwide definition [Text] / K.G. Alberti, P. Zimmet, J. Shaw / Lancet. – 2005. – Vol. 366, №9491. – P. 1059-1062. https://doi.org/10.1016/s0140-6736(05)67402-8

Chobanian A.V. The Seventh Report of the Joint National Commit – tî on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report [Text] / A. Chobanian, G. Bakris, H. Black [et al.] / JAMA. – 2003. – Vol. 289, №19. - P. 2560-2572. https://doi.org/10.1001/jama.289.19.2560

Guidelines Subcommittee. 1999 WHO ISH Guidelines for the management of hypertension [Text] // J.Hypertens. -1999. – Vol. 17. – P. 151-183. https://doi.org/10.1097/00004872-199917020-00001

American Diabetes Association. Diagnosis and classification of diabetes mellitus [Text] // Diabetes Care. – 2012. – Vol. 35, Suppl. 1. – P. 64-71. www.dtu.ox.ac.uk/homacalculator/index.php/

Cockcroft D.W., Gault M.H. Prediction of creatinine clearance from serum creatinine [Text] // Nephron. – 1976. – Vol. 16. – P. 31-41. https://doi.org/10.1159/000180580

Лакин Г.Ф. Биометрия [Текст]: учеб. пособие для биол. спец. вузов/ Г.Ф. Лакин. – 4-е изд., перераб. и доп. – М.: Высшая школа, 1990. – 352 с.

Petrossians P. The Liege Acromegaly Survey (LAS): a new software tool for the study of acromegaly [Text] / P. Petrossians, M. Tichomirowa, A.Stevenaert [et al.] / Ann. Endocrinol. (Paris). – 2012. – Vol. 73, №3. – P. 190-201. https://doi.org/10.1016/j.ando.2012.05.001

Arosio M. Predictors of morbidity and mortality in acromegaly: an Italian survey [Text]/ M. Arosio, G. Reimondo, E. Malchiodi [et al.] / Eur. J. Endocrinol. – 2012. – Vol. 167, №2. – P. 189-198. https://doi.org/10.1530/eje-12-0084

Weir M.R. Microalbuminuria and cardiovascular disease [Text] // Clin. J. Am. Soc. Nephrol. – 2007. – Vol. 2, №3. – P. 581-590. https://doi.org/10.2215/cjn.03190906